B+
Bull case
15%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
ICU
SeaStar MedicalDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
QUELIMMUNE is showing early hospital adoption, 82% year-over-year Q2 revenue growth, 91% gross margins, and expanding reimbursement infrastructure. Successful adult-AKI trial execution could create significant upside.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
A negative or inconclusive trial would materially impair the adult-AKI thesis.
Momentum
72
Value
37
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.50 · Bull $6.50 · Bear $1.30Analysis 2026-09-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $12.00
Why
Momentum72 · Δ7d -
Value37 · Δ7d -0.0
Sentiment44 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • A negative or inconclusive trial would materially impair the adult-AKI thesis.
- • Cash declined to $7.0 million amid a widening quarterly net loss, creating financing and dilution risk.
- • The pediatric market remains small, adult-AKI upside depends on trial success and FDA approval, enrollment is incomplete, losses are widening, and the $7 million cash balance raises financing and dilution risk.
Catalyst clock
2026-08-12
Q2 commercial traction confirmed, but profitability weakened
Lead driver: Sentiment · See AI snapshot
Momentum
72
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
44
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 72.3 / Value 36.6 / Sentiment 44.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-03. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$1.30
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$14.32M
Beta
-0.98
Shares Out
4.41M
P/E (TTM) · Derived
-0.6
P/S (TTM)
10.60
P/FCF (TTM) · Derived
-0.81
Rev YoY
+82.0%
EPS YoY
-48.3%
Gross Margin
+92.6%
Op Margin
-816.6%
Net Debt
-$11.46M
Current Ratio
1.89
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data